• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.多生物标志物与急性冠状动脉综合征后全因和特定原因死亡率风险的关联:PLATO 生物标志物研究的二次分析。
JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.
2
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.与氯吡格雷相比,替格瑞洛对非 ST 段抬高型急性冠脉综合征患者的影响与有无院内血运重建的关系:来自前瞻性随机血小板抑制和患者结局(PLATO)试验的一项亚研究。
Circulation. 2014 Jan 21;129(3):293-303. doi: 10.1161/CIRCULATIONAHA.113.004420. Epub 2013 Oct 29.
3
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.生物标志物和冠状动脉病变对非ST段抬高型急性冠状动脉综合征血运重建术后预后的预测作用
Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8.
4
Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score.采用 hsTnT、NT-proBNP 和 hsCRP 联合 GRACE 评分对急性冠脉综合征患者进行改良危险分层。
Eur Heart J Acute Cardiovasc Care. 2018 Mar;7(2):129-138. doi: 10.1177/2048872616684678. Epub 2016 Dec 28.
5
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.使用生物标志物预测房颤患者特定死因。
Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125.
6
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.生长分化因子-15 水平可预测急性冠脉综合征患者的大出血和心血管事件:来自 PLATO 研究的结果。
Eur Heart J. 2016 Apr 21;37(16):1325-33. doi: 10.1093/eurheartj/ehv491. Epub 2015 Sep 28.
7
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.骨保护素与急性冠状动脉综合征患者的大出血相关,但与心血管结局无关:来自 PLATO(血小板抑制和患者结局)试验的见解。
J Am Heart Assoc. 2018 Jan 12;7(2):e007009. doi: 10.1161/JAHA.117.007009.
8
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.B型利钠肽和N末端B型利钠肽原作为近期发生冠状动脉事件的2型糖尿病患者心血管疾病发病率和死亡率预测指标的作用
J Am Heart Assoc. 2017 May 29;6(6):e004743. doi: 10.1161/JAHA.116.004743.
9
Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event.无心血管既往事件人群的单一和多种心血管生物标志物。
Eur J Prev Cardiol. 2017 Oct;24(15):1648-1659. doi: 10.1177/2047487317717065. Epub 2017 Jun 23.
10
Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.生长分化因子-15作为急性心肌梗死患者的预后标志物
Eur Heart J. 2009 May;30(9):1057-65. doi: 10.1093/eurheartj/ehn600. Epub 2009 Jan 23.

引用本文的文献

1
Effect of Premature Acute Coronary Syndrome on Ocular Hemodynamics.早发急性冠状动脉综合征对眼部血流动力学的影响。
Int J Med Sci. 2025 Mar 3;22(7):1698-1707. doi: 10.7150/ijms.107842. eCollection 2025.
2
miR-203 Alleviates Myocardial Damage Caused by Acute Coronary Syndrome by Inhibiting CA125.微小RNA-203通过抑制CA125减轻急性冠状动脉综合征所致的心肌损伤。
Biochem Genet. 2025 Feb 28. doi: 10.1007/s10528-025-11069-4.
3
Biomarkers of residual risk and all-cause mortality after acute coronary syndrome.急性冠状动脉综合征后残余风险和全因死亡率的生物标志物。
Am J Prev Cardiol. 2025 Jan 14;21:100934. doi: 10.1016/j.ajpc.2025.100934. eCollection 2025 Mar.
4
Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.传统和新型生物标志物在诊断和预测冠状动脉疾病、急性冠状动脉综合征及心力衰竭预后中的综合质量分析:一项综合文献综述
J Cardiovasc Transl Res. 2024 Dec;17(6):1258-1285. doi: 10.1007/s12265-024-10540-8. Epub 2024 Jul 12.
5
Exploring the Role of GDF-15 in Inflammatory Bowel Disease: A Case-Controlled Study Comparing Crohn's Disease and Ulcerative Colitis with Non-Inflammatory Controls.探索生长分化因子-15在炎症性肠病中的作用:一项比较克罗恩病和溃疡性结肠炎与非炎症对照的病例对照研究。
Metabolites. 2024 Mar 25;14(4):185. doi: 10.3390/metabo14040185.
6
Predictive Value of Myocardial Markers for Early Postoperative Mortality in Children with Congenital Heart Disease.先天性心脏病患儿术后早期死亡率的心肌标志物预测价值
Pediatr Cardiol. 2025 Feb;46(2):324-331. doi: 10.1007/s00246-024-03404-0. Epub 2024 Feb 16.
7
Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.新型生物标志物及其在急性冠状动脉综合征诊断和预后中的作用
Life (Basel). 2023 Sep 29;13(10):1992. doi: 10.3390/life13101992.
8
Exploring the Potential of Proteome Analysis as a Promising Tool for Evaluation of Sudden Cardiac Death (SCD) in Forensic Settings: A Literature Review.探索蛋白质组分析在法医学中评估心源性猝死(SCD)的潜在价值:文献综述。
Int J Mol Sci. 2023 Sep 20;24(18):14351. doi: 10.3390/ijms241814351.
9
Growth Differentiation Factor-15 in Asian IHD Patients: Should We Use to Guide Therapeutic Decision?亚洲缺血性心脏病患者的生长分化因子-15:我们应该用它来指导治疗决策吗?
JACC Asia. 2023 Jun 20;3(3):472-474. doi: 10.1016/j.jacasi.2023.04.004. eCollection 2023 Jun.
10
Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities Study.生长分化因子 15 与出血事件风险:社区动脉粥样硬化风险研究。
J Am Heart Assoc. 2023 Mar 21;12(6):e023847. doi: 10.1161/JAHA.121.023847. Epub 2023 Mar 16.

本文引用的文献

1
Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study.非 ST 段抬高型心肌梗死患者经皮冠状动脉介入治疗时机:SWEDEHEART 研究。
Eur Heart J Qual Care Clin Outcomes. 2017 Jan 1;3(1):53-60. doi: 10.1093/ehjqcco/qcw044.
2
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.GFRAL 是 GDF15 的受体,是配体发挥抗肥胖作用所必需的。
Nat Med. 2017 Oct;23(10):1158-1166. doi: 10.1038/nm.4394. Epub 2017 Aug 28.
3
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.GDF15 的代谢作用是由孤儿受体 GFRAL 介导的。
Nat Med. 2017 Oct;23(10):1215-1219. doi: 10.1038/nm.4393. Epub 2017 Aug 28.
4
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.GFRAL 是 GDF15 的受体,该配体可促进小鼠和非人灵长类动物的体重减轻。
Nat Med. 2017 Oct;23(10):1150-1157. doi: 10.1038/nm.4392. Epub 2017 Aug 28.
5
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.基于生物标志物的风险模型预测稳定型冠心病患者的心血管死亡率。
J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030.
6
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.生长分化因子15与心房颤动大出血风险:来自长期抗凝治疗随机评估(RE-LY)试验的见解
Am Heart J. 2017 Aug;190:94-103. doi: 10.1016/j.ahj.2017.06.001. Epub 2017 Jun 6.
7
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.急性冠状动脉综合征后1个月时的生长分化因子15与大出血风险增加相关。
J Am Heart Assoc. 2017 Apr 14;6(4):e005580. doi: 10.1161/JAHA.117.005580.
8
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.生物标志物和冠状动脉病变对非ST段抬高型急性冠状动脉综合征血运重建术后预后的预测作用
Clin Chem. 2017 Feb;63(2):573-584. doi: 10.1373/clinchem.2016.261271. Epub 2016 Dec 8.
9
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.生长分化因子15预测稳定型冠心病的全因发病和死亡情况。
Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.
10
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.新型基于生物标志物的 ABC(年龄、生物标志物、临床病史)-房颤患者出血风险评分:一项推导和验证研究。
Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.

多生物标志物与急性冠状动脉综合征后全因和特定原因死亡率风险的关联:PLATO 生物标志物研究的二次分析。

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

机构信息

Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.

Uppsala Clinical Research Center, Uppsala, Sweden.

出版信息

JAMA Cardiol. 2018 Dec 1;3(12):1160-1166. doi: 10.1001/jamacardio.2018.3811.

DOI:10.1001/jamacardio.2018.3811
PMID:30427997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6583102/
Abstract

IMPORTANCE

Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes.

OBJECTIVE

To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality.

DESIGN, SETTING, AND PARTICIPANTS: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated.

MAIN OUTCOMES AND MEASURES

Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death.

EXPOSURES

At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined.

RESULTS

The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43).

CONCLUSIONS AND RELEVANCE

In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT00391872.

摘要

重要性

急性冠状动脉综合征事件发生后一年内的死亡率仍约为 5%。先前的研究评估了与全因或心血管死亡相关的生物标志物,但未评估多种原因导致的死亡。

目的

评估不同的生物标志物是否能提供与全因和病因特异性死亡率相关的信息。

设计、地点和参与者:血小板抑制和患者结局(PLATO)试验于 2006 年 10 月至 2008 年 7 月期间将 18624 例急性冠状动脉综合征患者随机分配至替格瑞洛或氯吡格雷治疗。在这项二级分析生物标志物亚研究中,有 17095 例患者参与。

主要结局和测量指标

心肌梗死、心力衰竭、心源性猝死/心律失常、出血、操作、其他血管原因和非血管原因导致的死亡,以及全因死亡。

暴露因素

在基线时,测定胱抑素-C、生长分化因子-15(GDF-15)、高敏 C 反应蛋白、高敏肌钙蛋白 I 和 T 以及 N 末端 B 型利钠肽前体(NT-proBNP)的水平。

结果

患者的中位(四分位间距)年龄为 62.0(54.0-71.0)岁。在 17095 例患者中,782 例(4.6%)在随访期间死亡。使用 Cox 模型对生物标志物与全因和病因特异性死亡率的连续相关性进行建模,并以风险比(HR)表示,比较上下四分位数。对于全因死亡率,NT-proBNP 和 GDF-15 是最强的标志物,校正后的 HR 分别为 2.96(95%CI,2.33-3.76)和 2.65(95%CI,2.17-3.24)。对于心力衰竭导致的死亡,NT-proBNP 与 8 倍风险增加相关,C 反应蛋白、GDF-15 和胱抑素-C 与 3 倍风险增加相关。对于心源性猝死/心律失常,NT-proBNP 与 4 倍风险增加相关,GDF-15 与风险翻倍相关。生长分化因子-15 与其他血管和非血管死亡的关联最强,并且可能与主要出血导致的死亡相关(HR,4.91;95%CI,1.39-17.43)。

结论和相关性

在急性冠状动脉综合征患者中,基于 NT-proBNP 和 GDF-15 与心力衰竭导致的死亡以及心律失常和心源性猝死导致的死亡相关,基线水平的 NT-proBNP 和 GDF-15 是与全因死亡相关的强标志物。生长分化因子-15 与其他血管或非血管原因导致的死亡以及可能与出血导致的死亡关联最强。

试验注册

ClinicalTrials.gov 标识符:NCT00391872。